Cancer, Pain
Conditions
Keywords
transdermal morphine, cancer, pain, bioavailability, pharmacokinetics, cancer related pain, stable baseline pain, currently taking opioids
Brief summary
Patients will participate in two arms of the trial, one in which morphine will be administered transdermally, and, after a 3 day wash out period, one in which morphine will be administered subcutaneously.
Detailed description
Patients will participate in two arms of the trial, one in which morphine will be administered transdermally, and, after a 3 day wash out period, one in which morphine will be administered subcutaneously. Blood draws will be done after both dosing methods in order to compare blood levels of morphine by the different routes.
Interventions
DRUGmorphine
Sponsors
Tom Baker Cancer Centre
Alberta Health services
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* Chronic cancer pain * Minimum baseline pain of 3/10 * No change in medications over 3 days prior to study period * Ability to give informed consent * Willingness to undergo repeated blood sampling
Exclusion criteria
* Use of morphine or codeine in 3 days prior to study * Known sensitivity to morphine * Prior anaphylactic reaction to any opioid * Clinically significant anemia
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| detectable morphine levels in serum | — |
Countries
Canada
Outcome results
None listed